Article thumbnail

Rosiglitazone: can meta-analysis accurately estimate excess cardiovascular risk given the available data? Re-analysis of randomized trials using various methodologic approaches

By Jan O Friedrich, Joseph Beyene and Neill KJ Adhikari
Topics: Correspondence
Publisher: BioMed Central
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. (2007). Alter DA: Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. JAMA
  2. (2007). Anonymous: Rosiglitazone: seeking a balanced perspective. Lancet
  3. (2008). DH: Comparison of cardiovascular outcomes in elderly patients with diabetes who initiated rosiglitazone vs pioglitazone therapy. Arch Intern Med
  4. (2007). Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.
  5. (2006). for the ADOPT Study Group: Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
  6. (2007). for the RECORD Study Group: Rosiglitazone evaluated for cardiovascular outcomes – an interim analysis.
  7. (2009). Furberg CD: Thiazolidinediones and cardiovascular outcomes in type 2 diabetes. Heart
  8. (2007). Inclusion of zero total event trials in meta-analyses maintains analytic consistency and incorporates all available data. BMC Med Res Methodol
  9. (2007). Localio A: Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. Stat Med
  10. (2007). Loke YK, Furberg CD: Long-term risk of cardiovascular events with rosiglitazone. A meta-analysis. JAMA
  11. (2007). Loke YK, Furberg CD: Thiazolidinediones and heart failure: a teleo-analysis. Diabetes Care
  12. (2007). Nesto RW: Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet
  13. (2005). on behalf of the PROactive investigators: Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet
  14. (2004). PC: What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat Med
  15. (2007). Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus. A meta-analysis of randomized trials.
  16. (2007). Rosiglitazone and cardiovascular risk.
  17. (2007). Rosiglitazone for type 2 diabetes mellitus. Cochrane Database Syst Rev
  18. (2007). S: Uncertain effects of rosiglitazone on the risk of myocardial infarction and cardiovascular death. Ann Intern Med
  19. (2007). The rosiglitazone story – lessons from an FDA advisory committee meeting.
  20. (2007). Wilding JPH: A randomized, placbocontrolled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association functional class I or II heart failure.
  21. (2009). Zinman B: Medical Management of Hyperglycemia in Type 2 Diabetes: a Consensus Algorithm for the Initiation and Adjustment of Therapy. Diabetes Care

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.